| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
To elucidate the clinical characteristics of hepatitis B virus reactivation (HBV-R), we performed a prospective long-term study of patients who receive immunosuppressive or cytotoxic therapy. We enrolled 229 patients with anti-HBc. HBV DNA levels were measured every month to 3 months by a real-time PCR method. The mean observation period was 24 months (range: 2-61 months). Entecavir was administered to all of 20 patients with more than 2.1 log/ml of HBV DNA at the enrollment. In HBsAg-negative patients, HBV was reactivated in 3/30 (10%) ML patients treated with rituximab combination therapy, and 5/19 (26%) patients with HSCT. In RA patients, HBV reactivation occurred in 3/88 (3%) patients. Entecavir inhibited HBV amplification and prevented HBV-associated hepatic failure in patients with HBV reactivation. Mutations in the 'a' determinant region with amino acid replacement were detected in 4 of the 8 patients with HBV-R.
|
